A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial

Simone Vigod, Neesha Hussain-Shamsy, Sophie Grigoriadis, Louise M Howard, Kelly Metcalfe, Tim F Oberlander, Carrie Schram, Donna E Stewart, Valerie H Taylor, Cindy-Lee Dennis, Simone Vigod, Neesha Hussain-Shamsy, Sophie Grigoriadis, Louise M Howard, Kelly Metcalfe, Tim F Oberlander, Carrie Schram, Donna E Stewart, Valerie H Taylor, Cindy-Lee Dennis

Abstract

Background: Many women with depression experience significant difficulty making a decision about whether or not to use antidepressant medication in pregnancy. Patient decision aids (PDAs) are tools that assist patients in making complex health decisions. PDAs can reduce decision-making difficulty and lead to better treatment outcomes. We describe the methods for a pilot randomized controlled trial of an interactive web-based PDA for women who are having difficulty deciding about antidepressant drug use in pregnancy.

Methods/design: This is a pilot randomized controlled trial that aims to assess the feasibility of a larger, multi-center efficacy study. The PDA aims to help a woman: (1) understand why an antidepressant is being recommended, (2) be knowledgeable about potential benefits and risks of treatment and non-treatment with antidepressants, and (3) be clear about which benefits and risks are most important to her, with the goal of improving confidence in her decision-making. We include women aged 18 years or older who are: (1) planning a pregnancy or are pregnant (gestational age less than 30 weeks), (2) diagnosed with major depressive disorder, (3) deciding whether or not to use a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressant in pregnancy, and (4) having at least moderate decision-making difficulty as per a Decisional Conflict Scale (DCS) Score ≥25. Participants are randomized to receive the PDA or an informational resource sheet via a secure website, and have access to the stated allocation until their final study follow-up. The primary outcomes of the pilot study are feasibility of recruitment and retention, acceptability of the intervention, and adherence to the trial protocol. The primary efficacy outcome is DCS score at 4 weeks post randomization, with secondary outcomes including depressive and anxiety symptoms.

Discussion: Our PDA represents a key opportunity to optimize the decision-making process for women around antidepressants in pregnancy, leading to effective decision-making and optimizing improved maternal and child outcomes related to depression in pregnancy. The electronic nature of the PDA will facilitate keeping it up-to-date, and allow for widespread dissemination after efficacy is demonstrated.

Trial registration: This trial is registered on ClinicalTrials.Gov under the identifier NCT02308592 (first registered: 2 December 2014).

Figures

Fig. 1
Fig. 1
Trial scheme for a pilot randomized control trial for a patient decision aid (PDA) for antidepressant use in pregnancy

References

    1. Bennett HA, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103(4):698–709. doi: 10.1097/01.AOG.0000116689.75396.5f.
    1. Gavin NI, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071–83. doi: 10.1097/01.AOG.0000183597.31630.db.
    1. Wisner KL, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557–66. doi: 10.1176/appi.ajp.2008.08081170.
    1. Marcus SM. Depression during pregnancy: rates, risks and consequences – Motherisk Update 2008. Can J Clin Pharmacol. 2009;16(1):e15–22.
    1. Beck CT. The effects of postpartum depression on child development: a meta-analysis. Arch Psychiatr Nurs. 1998;12(1):12–20. doi: 10.1016/S0883-9417(98)80004-6.
    1. Hammen C, Brennan PA. Severity, chronicity, and timing of maternal depression and risk for adolescent offspring diagnoses in a community sample. Arch Gen Psychiatry. 2003;60(3):253–8. doi: 10.1001/archpsyc.60.3.253.
    1. Martins C, Gaffan EA. Effects of early maternal depression on patterns of infant-mother attachment: a meta-analytic investigation. J Child Psychol Psychiatry. 2000;41(6):737–46. doi: 10.1111/1469-7610.00661.
    1. Murray L. The impact of postnatal depression on infant development. J Child Psychol Psychiatry. 1992;33(3):543–61. doi: 10.1111/j.1469-7610.1992.tb00890.x.
    1. Nulman I, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159(11):1889–95. doi: 10.1176/appi.ajp.159.11.1889.
    1. O’Hara MW, Swain AM. Rates and risk of postpartum depression – A meta-analysis. Int Rev Psychiatry. 1996;8(1):37–54. doi: 10.3109/09540269609037816.
    1. Sinclair D, Murray L. Effects of postnatal depression on children’s adjustment to school. Teacher’s reports. Br J Psychiatry. 1998;172:58–63. doi: 10.1192/bjp.172.1.58.
    1. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry. 1998;59(Suppl 2):53–61.
    1. Weikum WM, et al. Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc Natl Acad Sci U S A. 2012;109(Suppl 2):17221–7. doi: 10.1073/pnas.1121263109.
    1. CANMAT Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001;46(Suppl 1):5S–90S.
    1. Dennis CL. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. J Clin Psychiatry. 2004;65(9):1252–65. doi: 10.4088/JCP.v65n0915.
    1. Dennis CL. Preventing postpartum depression part I: a review of biological interventions. Can J Psychiatry. 2004;49(7):467–75.
    1. Dennis CL. Preventing postpartum depression part II: a critical review of nonbiological interventions. Can J Psychiatry. 2004;49(8):526–38.
    1. Dennis CL, Stewart DE. Treatment of postpartum depression, part 1: a critical review of biological interventions. J Clin Psychiatry. 2004;65(9):1242–51. doi: 10.4088/JCP.v65n0914.
    1. Gjerdingen D. The effectiveness of various postpartum depression treatments and the impact of antidepressant drugs on nursing infants. J Am Board Fam Pract. 2003;16(5):372–82. doi: 10.3122/jabfm.16.5.372.
    1. Sharma V. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2002;3(10):1421–31. doi: 10.1517/14656566.3.10.1421.
    1. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17. doi: 10.1176/ajp.2006.163.11.1905.
    1. Cohen LS, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499–507. doi: 10.1001/jama.295.5.499.
    1. Pedersen LH, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569. doi: 10.1136/bmj.b3569.
    1. Chambers CD, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87. doi: 10.1056/NEJMoa052744.
    1. Kieler H, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012. doi: 10.1136/bmj.d8012.
    1. Wen SW, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194(4):961–6. doi: 10.1016/j.ajog.2006.02.019.
    1. Wisner KL, et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? Am J Psychiatry. 2013;170(5):485–93. doi: 10.1176/appi.ajp.2012.11121873.
    1. Casper RC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142(4):402–8. doi: 10.1067/mpd.2003.139.
    1. Chambers CD, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010–5. doi: 10.1056/NEJM199610033351402.
    1. Cohen LS, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48(10):996–1000. doi: 10.1016/S0006-3223(00)00877-5.
    1. Costei AM, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11):1129–32. doi: 10.1001/archpedi.156.11.1129.
    1. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55(7):503–8. doi: 10.1007/s002280050664.
    1. Kulin NA, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609–10. doi: 10.1001/jama.279.8.609.
    1. Laine K, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720–6. doi: 10.1001/archpsyc.60.7.720.
    1. Levinson-Castiel R, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173–6. doi: 10.1001/archpedi.160.2.173.
    1. Nordeng H, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90(3):288–91. doi: 10.1080/080352501300067596.
    1. Oberlander TF, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res. 2002;51(4):443–53. doi: 10.1203/00006450-200204000-00008.
    1. Pastuszak A, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) JAMA. 1993;269(17):2246–8. doi: 10.1001/jama.1993.03500170076037.
    1. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055–61. doi: 10.1176/appi.ajp.159.12.2055.
    1. Stiskal JA, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84(2):F134–5. doi: 10.1136/fn.84.2.F134.
    1. Nulman I, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012;169(11):1165–74. doi: 10.1176/appi.ajp.2012.11111721.
    1. Mulder EJ, et al. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology. 2011;36(10):1961–71. doi: 10.1038/npp.2011.67.
    1. O’Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15(1):25–30. doi: 10.1177/0272989X9501500105.
    1. Walton GD, Ross LE, Stewart DE, Grigoriadis S, Dennis CL, Vigod S. Decisional conflict among women considering antidepressant medication use in pregnancy. Arch Womens Ment Health. 2014;17(6):493–501. doi: 10.1007/s00737-014-0448-1.
    1. Battle CL, et al. Perinatal antidepressant use: understanding women’s preferences and concerns. J Psychiatr Pract. 2013;19(6):443–53. doi: 10.1097/01.pra.0000438183.74359.46.
    1. Coulter A, Kryworuchko J, Mullen PD, Ng CJ, Stilwell D, van der Weijden T. Chapter A: using a systematic development process, in update of the International Patient Decision Aids Standards (IPDAS) Collaborations’ Background Document, Llewellyn-Thomas HA, Volk RJ, editors. 2012. pp. 1–16. . Accessed 23 Feb 2016.
    1. Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;10:CD001431.
    1. Kasper JF, Mulley AG, Jr, Wennberg JE. Developing shared decision-making programs to improve the quality of health care. QRB Qual Rev Bull. 1992;18(6):183–90.
    1. Levine MN, et al. A bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992;117(1):53–8. doi: 10.7326/0003-4819-117-1-53.
    1. O’Connor AM, Jacobsen MJ, Stacey D. An evidence-based approach to managing women’s decisional conflict. J Obstet Gynecol Neonatal Nurs. 2002;31(5):570–81. doi: 10.1111/j.1552-6909.2002.tb00083.x.
    1. O’Connor AM, et al. The Ottawa patient decision aids. Eff Clin Pract. 1999;2(4):163–70.
    1. Gibson J, et al. A systematic review of studies validating the Edinburgh Postnatal Depression Scale in antepartum and postpartum women. Acta Psychiatr Scand. 2009;119(5):350–64. doi: 10.1111/j.1600-0447.2009.01363.x.
    1. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782–6. doi: 10.1192/bjp.150.6.782.
    1. Dennis CL, Coghlan M, Vigod S. Can we identify mothers at-risk for postpartum anxiety in the immediate postpartum period using the State-Trait Anxiety Inventory? J Affect Disord. 2013;150(3):1217–20. doi: 10.1016/j.jad.2013.05.049.
    1. Metcalfe KA, et al. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet. 2007;72(3):208–17. doi: 10.1111/j.1399-0004.2007.00859.x.
    1. Watson M, et al. Measuring contamination in an injury prevention randomized controlled trial. Int J Inj Contr Saf Promot. 2005;12(3):197–9. doi: 10.1080/17457300500088949.
    1. Cook JA, Ramsay CR, Fayers P. Statistical evaluation of learning curve effects in surgical trials. Clin Trials. 2004;1(5):421–7. doi: 10.1191/1740774504cn042oa.
    1. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31(2):180–91. doi: 10.1002/nur.20247.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner